Lv1
42 积分 2025-11-09 加入
Hyper-CVAD and Sequential Blinatumomab Without and With Inotuzumab in Young Adults With Newly Diagnosed Philadelphia Chromosome-Negative B-Cell Acute Lymphoblastic Leukemia
7天前
已完结
Reduced-dose chemotherapy and blinatumomab as induction treatment for newly diagnosed Ph-negative B-cell precursor acute lymphoblastic leukemia: a phase 2 trial
10天前
已完结
Minimal Residual Disease Response-Adapted Therapy in Newly Diagnosed Multiple Myeloma: Final Report of the Multicenter, Single-Arm, Phase 2 MASTER Trial
1个月前
已完结
Time to Stop? Rethinking the Duration of Maintenance Treatment in Multiple Myeloma
1个月前
已完结
Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial
1个月前
已完结
Continuous or Fixed-Duration Maintenance Therapy in Multiple Myeloma
1个月前
已完结
Global guideline for the diagnosis and management of rare yeast infections: an initiative of the ECMM in cooperation with ISHAM and ASM
3个月前
已完结
Invasive infections due to Saprochaete and Geotrichum species: Report of 23 cases from the FungiScope Registry
3个月前
已完结
Inotuzumab ozogamicin, an anti-CD22–calecheamicin conjugate, for refractory and relapsed acute lymphocytic leukaemia: a phase 2 study
3个月前
已完结
皖公网安备34019202002308
